Skip to main content

Table 1 Description of patients with HIV-1 and the control group

From: Epstein-Barr virus variation in people living with human immunodeficiency virus in southeastern China

Category

HIV (N = 162)

Non-HIV (N = 52)

P-value

Age

47.5 (35.9, 58.9)

53.5 (44.0, 68.5)

0.018

Gender

  

0.001

Male

142 (87.65)

31 (59.62)

 

Female

20 (12.35)

21 (40.38)

 

Education

  

0.001

Primary school

43 (26.54)

32 (61.54)

 

Secondary school

83 (51.23)

15 (28.85)

 

Undergraduate or above

36 (22.22)

5 (9.62)

 

Comorbidities

   

Lymphomas

38 (23.46)

17 (32.69)

0.204

Diseases other than lymphoma

124 (76.54)

35 (67.31)

 

HAART

   

INSTI-based regimens

78 (48.15)

–

 

PI-based regimens

5 (3.09)

–

 

NRTI-based regimens

79 (48.77)

–

 

HAART exposure duration

   

 ≤ 6 months

116

–

 

6–12 months

42

–

 

12–24 months

2

–

 

 ≥ 24 months

2

–

 

CD4+ T cell count(cells/mm3)

96.50 (21.75–241.50)

–

 

CD8 + T cell count(cells/mm3)

455.50 (250.25–750.00)

–

 

CD4+/CD8+

0.19 (0.08–0.47)

–

 
  1. Data was are median (IQR) or n (%); HAART: highly active antiretroviral therapy, NRTIs: Nucleotide Reverse Transcriptase Inhibitors, NNRTIs: Non-nucleotide Reverse Transcriptase Inhibitors, INSTIs: Integrase strand transfer inhibitors
Back to article page

Virology Journal

ISSN: 1743-422X